$PEPG News

HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $20 Price Target

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate

PepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort

Craig-Hallum Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $11

PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PepGen Files For $400M Shelf Registration And $100M At-The-Market Stock Offering

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

Wedbush Maintains Outperform on PepGen, Lowers Price Target to $4

PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate

Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5

PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

PepGen shares are trading lower after the company announced clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1. Also, Wedbush lowered its price target on the stock from $9 to $5.

PepGen shares are trading lower after the company announced clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1. Also, Wedbush lowered its price target on the stock from $9 to $5.

Wedbush Maintains Outperform on PepGen, Lowers Price Target to $5

Why Is PepGen Stock Sinking Tuesday?